What is Diagnosys?
Diagnosys LLC operates at the intersection of advanced medical instrumentation and life sciences research. With a legacy spanning over four decades, the company specializes in the development of sophisticated visual function test systems. Their product portfolio, anchored by the Celeris platform, provides researchers with high-precision electroretinography and psychophysical testing capabilities. By facilitating dual-function stimulator-electrode integration, Diagnosys enables academic and commercial institutions to conduct rigorous visual electrophysiology studies, effectively bridging the gap between laboratory innovation and clinical application.
How much funding has Diagnosys raised?
Diagnosys has raised a total of $506K across 2 funding rounds:
Debt
$150K
Debt
$356K
Debt (2020): $150K with participation from PPP
Debt (2021): $356K led by PPP
Key Investors in Diagnosys
PPP
Public-Private Partnership
What's next for Diagnosys?
With this major enterprise-level funding, Diagnosys is well-positioned to accelerate its R&D initiatives and expand its footprint in the global clinical trial services market. The strategic allocation of this capital will likely focus on enhancing the technological capabilities of their existing product suite while scaling operational support for their international clientele. As the demand for high-fidelity visual assessment tools continues to rise within the pharmaceutical and biotech sectors, Diagnosys remains poised to leverage its deep domain expertise to capture additional market share and drive long-term value in the visual diagnostics space.
See full Diagnosys company page
